355 Alhambra Circle
Suite 801
Coral Gables, FL 33134
United States
305 420 3200
https://www.catalystpharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 167
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Patrick J. McEnany | Co-Founder & Chairman | 1.2M | N/D | 1947 |
Mr. Richard John Daly M.B.A. | President, CEO & Director | 63.12k | N/D | 1961 |
Dr. Steven R. Miller Ph.D. | Executive VP, COO & Chief Scientific Officer | 809.03k | N/D | 1962 |
Dr. Gary Ingenito M.D., Ph.D. | Chief Medical & Regulatory Officer | 751.85k | N/D | 1956 |
Mr. Jeffrey Del Carmen | Executive VP & Chief Commercial Officer | 711.7k | N/D | 1971 |
Mr. Michael W. Kalb CPA | Executive VP & CFO | N/D | N/D | 1971 |
Ms. Mary Coleman | VP & Head of Investor Relations | N/D | N/D | N/D |
Mr. Brian Elsbernd J.D. | Chief Compliance Officer & Chief Legal Officer | 311.42k | N/D | 1964 |
Mr. Pete Curry Sr. | Vice President of Sales | N/D | N/D | N/D |
Dr. Stanley Iyadurai M.D., Ph.D. | Senior Vice President of Medical Affairs & Drug Discovery | N/D | N/D | N/D |
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
La calificación ISS Governance QuickScore de Catalyst Pharmaceuticals, Inc. a partir del 1 de marzo de 2024 es 5. Las puntuaciones principales son Auditoría: 9; Junta: 4; Derechos del accionista: 3; Compensación: 7.